Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Leases (2019 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Operating Leases for 6 consecutive years, with $565000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Operating Leases fell 32.17% to $565000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $565000.0, a 32.17% decrease, with the full-year FY2024 number at $565000.0, down 32.17% from a year prior.
  • Operating Leases was $565000.0 for Q4 2024 at Whitehawk Therapeutics, down from $624000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.8 million in Q2 2022 to a low of $9955.0 in Q2 2020.
  • A 5-year average of $810320.4 and a median of $710000.0 in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 96.54% in 2020, then soared 229.06% in 2022.
  • Whitehawk Therapeutics' Operating Leases stood at $9955.0 in 2020, then soared by 5977.35% to $605000.0 in 2021, then surged by 109.42% to $1.3 million in 2022, then crashed by 34.25% to $833000.0 in 2023, then tumbled by 32.17% to $565000.0 in 2024.
  • Per Business Quant, the three most recent readings for WHWK's Operating Leases are $565000.0 (Q4 2024), $624000.0 (Q3 2024), and $682000.0 (Q2 2024).